Merck and Kelun-Biotech reported a Phase 3 result for sacituzumab tirumotecan (sac-TMT) plus pembrolizumab (Keytruda) that cut the risk of disease progression or death by 65% versus Keytruda alone in treatment-naïve, PD-L1-positive non-small cell lung cancer in China. In the OptiTROP-Lung05 study, median PFS was not reached in the combination arm versus 5.7 months with Keytruda, with a reported response rate of just over 70% versus 42%. Key overall survival results were not mature at the September 2025 cutoff.